UT-MD Anderson Cancer Center: Metastasis-Directed Radiation Therapy Plus Hormone Therapy Improves Progression-Free Survival for Men With Advanced Prostate Cancer
April 07, 2023
April 07, 2023
HOUSTON, Texas, April 7 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were published today in JAMA Oncology and were first presented at th . . .
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were published today in JAMA Oncology and were first presented at th . . .